Clinical Trial Detail

NCT ID NCT03653507
Title A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Astellas Pharma Global Development, Inc.
Indications

gastroesophageal junction adenocarcinoma

stomach cancer

gastric adenocarcinoma

gastroesophageal cancer

Therapies

Capecitabine + Oxaliplatin

Capecitabine + Oxaliplatin + Zolbetuximab

Age Groups: senior adult

Additional content available in CKB BOOST